How can you tailor therapeutic strategies based on disease aggressiveness?

VeriStrat® is a blood-based predictive and prognostic proteomic test for patients with advanced non-small cell lung cancer who test negative for EGFR mutations (EGFR wild-type) or whose EGFR mutation status is unknown.

VeriStrat assesses disease aggressiveness, classifying patients as either VeriStrat Good or VeriStrat Poor.

VeriStrat identifies the host patient response to the tumor by measuring several acute phase reactant proteins in the blood. VeriStrat Poor signature correlates with a more aggressive disease; VeriStrat Good signature correlates with a more favorable prognosis. In addition to being prognostic, VeriStrat is predictive of differential treatment benefit when selecting between single-agent treatment options.

Learn more: